Evidence map›Paper›PMID 32973697›Full record

ReviewFrontiers in microbiology2020

Probiotics at War Against Viruses: What Is Missing From the Picture?

Santosh Kumar Tiwari, Leon M T Dicks, Igor V Popov, Alena Karaseva, Alexey M Ermakov, Alexander Suvorov, John R Tagg, Richard Weeks, Michael L Chikindas

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
1.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 102 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Biotechnological potential of Lacticaseibacillus paracasei Shirota for bioemulsifier, bacteriocin and lipase production.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Santosh Kumar TiwariDepartment of Genetics, Maharshi Dayanand University, Rohtak, India.
Leon M T DicksDepartment of Microbiology, Stellenbosch University, Stellenbosch, South Africa.
Igor V PopovCenter for Agro-Biotechnology, Faculty of Bioengineering and Veterinary Medicine, Don State Technical University, Rostov-on-Don, Russia.
Alena KarasevaInstitute of Experimental Medicine, Saint Petersburg, Russia.
Alexey M ErmakovCenter for Agro-Biotechnology, Faculty of Bioengineering and Veterinary Medicine, Don State Technical University, Rostov-on-Don, Russia.
Alexander SuvorovInstitute of Experimental Medicine, Saint Petersburg, Russia.
John R TaggBLIS Technologies Ltd., Dunedin, New Zealand.
Richard WeeksHealth Promoting Naturals Laboratory, School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, Brunswick, NJ, United States.
Michael L ChikindasCenter for Agro-Biotechnology, Faculty of Bioengineering and Veterinary Medicine, Don State Technical University, Rostov-on-Don, Russia.
Don State Technical University · RUInstitute of Experimental Medicine · RUMaharshi Dayanand University · INRutgers, The State University of New Jersey · USStellenbosch University · ZASt Petersburg University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our world is now facing a multitude of novel infectious diseases. Bacterial infections are treated with antibiotics, albeit with increasing difficulty as many of the more common causes of infection have now developed broad spectrum antimicrobial resistance. However, there is now an even greater challenge from both old and new viruses capable of causing respiratory, enteric, and urogenital infections. Reports of viruses resistant to frontline therapeutic drugs are steadily increasing and there is an urgent need to develop novel antiviral agents. Although this all makes sense, it seems rather strange that relatively little attention has been given to the antiviral capabilities of probiotics. Over the years, beneficial strains of lactic acid bacteria (LAB) have been successfully used to treat gastrointestinal, oral, and vaginal infections, and some can also effect a reduction in serum cholesterol levels. Some probiotics prevent gastrointestinal dysbiosis and, by doing so, reduce the risk of developing secondary infections. Other probiotics exhibit anti-tumor and immunomodulating properties, and in some studies, antiviral activities have been reported for probiotic bacteria and/or their metabolites. Unfortunately, the mechanistic basis of the observed beneficial effects of probiotics in countering viral infections is sometimes unclear. Interestingly, in COVID-19 patients, a clear decrease has been observed in cell numbers of

Indexed as

antiviralbacteriocinsCOVID-19gut microbiotaimmunityprobioticsSARS-CoV-2viruses

Identifiers

PMID32973697
PMCPMC7468459
OpenAlexW3060604810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.